Tumor monocyte content predicts immunochemotherapy outcomes in esophageal adenocarcinoma

For inoperable esophageal adenocarcinoma (EAC), identifying patients likely to benefit from recently approved immunochemotherapy (ICI+CTX) treatments remains a key challenge. We address this using a uniquely designed window-of-opportunity trial (LUD2015-005), in which 35 inoperable EAC patients rece...

Полное описание

Библиографические подробности
Главные авторы:	Carroll, TM, Chadwick, JA, Owen, RP, White, MJ, Kaplinsky, J, Peneva, I, Frangou, A, Xie, PF, Chang, J, Roth, A, Amess, B, James, SA, Rei, M, Fuchs, HS, McCann, KJ, Omiyale, AO, Jacobs, B-A, Lord, SR, Norris-Bulpitt, S, Dobbie, ST, Griffiths, L, Ramirez, KA, Ricciardi, T, Macri, MJ, Ryan, A, Venhaus, RR, Van den Eynde, BJ, Karydis, I, Schuster-Böckler, B, Middleton, MR, Lu, X
Другие авторы:	LUD2015-005 Project Team
Формат:	Journal article
Язык:	English
Опубликовано:	Cell Press 2023

Tumor monocyte content predicts immunochemotherapy outcomes in esophageal adenocarcinoma

Схожие документы